Invitation | Harbour BioMed Investor Day 2022

Harbour BioMed to Present the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody Porustobart with Unique Treg Depletion Mechanism at ESMO I-O 2022

 Cambridge, MA, Rotterdam, NL, Suzhou, CN— Nov 25, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced that ...

Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

CAMBRIDGE, MA— November 21, 2022   Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution...

Harbour BioMed Launches Nona Biosciences’ “Ideas to IND” Preclinical Solutions Business to Accelerate Global Biotherapeutic Innovation

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2022   Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned sub...

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 11, 2022   Harbour BioMed (the “Company”, HKEX: 02142) today announced that N...

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 20, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 13, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceuti...

Harbour BioMed Enters into Agreement with CSPC Pharmaceutical Group Limited for Batoclimab (HBM9161) in Greater China

Cambridge, MA, Rotterdam, NL, Suzhou, CN - October 10, 2022   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical com...

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 27, 2022   Harbour BioMed (“HBM”, HKEX: 02142) today announces that it has com...

Harbour BioMed Announces 2022 Interim Results: Revenue Grows by 1155% with Landmark Acceleration in Core Innovation Strength and Platforms Value

CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands -  August 31, 2022   Harbour BioMed (“HBM”, or the "Company”; HK...